Yes, Tetanus Immune Globulin (TIG) Can Be Safely Given to Patients with Tetanus Toxoid Allergy
If a patient has a documented allergy to tetanus toxoid vaccine, tetanus immune globulin (TIG) is the appropriate and safe alternative for passive immunization, as it contains antibodies rather than the toxoid antigen that triggers the allergic reaction. 1
Key Distinction: Different Products, Different Mechanisms
The critical point is that TIG and tetanus toxoid are fundamentally different products:
- Tetanus toxoid vaccine contains the tetanus toxin protein (toxoid) that stimulates active immunity but can trigger allergic reactions in sensitized individuals 2
- Tetanus immune globulin (TIG) contains pre-formed human antibodies (IgG) against tetanus toxin, providing immediate passive immunity without exposing the patient to the toxoid antigen 3
When TIG Should Be Used Instead of Toxoid
ACIP guidelines explicitly state: "If a contraindication to using tetanus-toxoid-containing preparations exists for a person who has not completed a primary series of tetanus toxoid immunization and that person has a wound that is neither clean nor minor, only passive immunization should be given using tetanus IG (TIG)." 1
This recommendation applies to patients with:
- History of anaphylaxis to tetanus toxoid
- Severe hypersensitivity reactions to previous tetanus toxoid doses
- Documented IgE-mediated allergy to tetanus toxoid 2
Safety Profile of TIG
The FDA drug label for TIG indicates that true allergic responses to human immunoglobulin preparations are rare 3. The product:
- Should not be given intravenously (IM only)
- Does not require skin testing before administration
- Contains human-derived antibodies, not the allergenic tetanus toxoid protein
- Has epinephrine available as standard precaution, though systemic reactions are uncommon 3
Important Caveats
Do not perform skin testing with TIG - the FDA label explicitly warns that intradermal injection of concentrated IgG solutions causes localized inflammation that can be misinterpreted as an allergic reaction, potentially leading physicians to withhold needed treatment 3
Dosing for wound management:
- Adults: 250 units IM
- Children: May calculate by body weight (4.0 units/kg) or give full 250-unit dose 3
- Administer in different site from any other injections
The Allergy is to Toxoid, Not Immunoglobulin
Research confirms that patients with tetanus toxoid allergy produce IgE antibodies against specific tetanus neurotoxin proteins (150 kDa and 50 kDa), which can persist for at least 5 years 2. These antibodies react to the toxoid antigen in the vaccine, not to human immunoglobulin preparations like TIG.
Bottom line: TIG provides the necessary passive protection without exposing the allergic patient to the offending antigen, making it both safe and indicated in this clinical scenario.